Anavex Presents Encouraging Results of Alzheimer’s Therapy Phase 1 Trial

Anavex Presents Encouraging Results of Alzheimer’s Therapy Phase 1 Trial

clinical trialBiopharmaceutical company Anavex Life Sciences Corp. recently presented encouraging results from their phase 1 clinical trial, a study testing the company's lead investigational oral treatment for Alzheimer's disease, Anavex 2-73, at CNS Summit 2014 in Boca Raton, Florida. After assessing the drug's safety and effectiveness, the medication is expected to be able to prevent, halt, and/or reverse the course of the disease. The company is now planning phase 2a trial of ANAVEX 2-73, as well as ANAVEX PLUS, the combination of ANAVEX 2-73 and donepezil (Aricept).

The phase 1 clinical trial demonstrated that the treatment is safe and well tolerated, suggesting a favorable pharmacokinetics profile. In addition, the randomized, double-blind, placebo-controlled study demonstrated that no severe adverse events were registered. Some of the adverse events reported include moderate and reversible headache and dizziness, which are common symptoms associated with drugs that target central nervous system (CNS) conditions, such as Alzheimer's.

"We are extremely encouraged by the strong safety profile of ANAVEX 2-73 as evidenced by the Phase 1 trial data. Treatment of Alzheimer's disease generally re

Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *